Bio-Rad set to acquire Stilla Technologies

HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced plans to acquire Stilla Technologies, a developer of next-generation digital PCR solutions. According to InvestingPro data, Bio-Rad maintains a strong financial position with a healthy current ratio of 6.14 and operates with moderate debt levels. The transaction is expected to be finalized by the end of the third quarter of 2025, pending regulatory approvals and customary closing conditions.

Stilla Technologies, operating out of France and the U.S., is recognized for its Nio (NYSE:NIO)® family of digital PCR systems, which are utilized in a variety of applications, including oncology diagnostics, cell and gene therapy, and infectious diseases. This move is poised to enhance Bio-Rad’s existing digital PCR portfolio and accelerate the development of new digital PCR technologies.

Norman Schwartz, CEO of Bio-Rad Laboratories, stated that the acquisition aligns with the company’s strategy to broaden its business in applied research and clinical diagnostics, areas that demand higher automation and throughput capabilities. Jim Barry, EVP and President of Bio-Rad’s Life Science Group, emphasized the complementary nature of Stilla’s platform with Bio-Rad’s upcoming QX Continuum™ system, which together aim to address the full spectrum of digital PCR applications.

Rémi Dangla, CEO of Stilla Technologies, expressed enthusiasm about the merger, anticipating that the combined expertise and global reach of both companies will deliver significant value to customers in applied research and biopharma.

Bio-Rad, headquartered in Hercules, California, operates globally with approximately 7,700 employees and reported revenues of $2.6 billion in 2024. The company serves a diverse customer base, including universities, research institutions, and various laboratories. Recent InvestingPro analysis suggests the stock is currently undervalued, despite a challenging week that saw a 9.57% decline in share price. For detailed insights and additional ProTips about Bio-Rad’s valuation, investors can access the comprehensive Pro Research Report available on InvestingPro.

This announcement may contain forward-looking statements subject to risks and uncertainties, including the timing and completion of the proposed transaction, the ability to obtain necessary regulatory approvals, and the anticipated benefits of the acquisition. The integration of the acquired business and the launch of Bio-Rad’s QX Continuum system are also factors that could influence the transaction’s success. InvestingPro analysts project positive net income growth for the company this year, with an EPS forecast of $10.38 for 2024, suggesting potential upside for investors following recent market developments.

The acquisition is based on a press release statement and reflects Bio-Rad’s continued commitment to advancing science and technology in the life sciences sector.

In other recent news, Oncocyte Corp. has successfully secured a funding round of $29.1 million, primarily intended to advance its FDA In-Vitro Diagnostic (IVD) transplant assay program. The funding round, led by existing investors including Bio-Rad Laboratories, is expected to facilitate the program’s clearance and commercial launch. The assay’s design aims to be easily adopted by transplant centers, offering rapid results for enhanced decision-making.

Oncocyte’s management team expressed belief in the technology’s potential to enhance patient care in transplant diagnostics. The company’s technology has shown potential to detect signs of kidney transplant rejection significantly earlier than current standards. Oncocyte’s CFO, Andrea James, highlighted the company’s financial discipline and commitment to capital stewardship in preparation for growth in the global transplant testing market, which stands at $1 billion.

The funding round was priced at $2.05 per share and included the sale of both common stock and pre-funded warrants. Needham & Company acted as the financial advisor to Oncocyte for this transaction. These recent developments reflect Oncocyte’s ongoing commitment to advancing its diagnostic technology in the transplant field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.